1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Earnings

GSK In 'Countdown Mode' To Consumer Split As Full Year Sales Slip Back

 
• By Tom Gallen

Two months on from GSK’s rejection of a £50bn bid for Consumer Healthcare from Unilever – and with other suitors seemingly yet to materialize – CEO Emma Walmsley is pressing ahead with the plan to spin off the business in mid-2022. GSK will be buoyed by a strong showing by Consumer Healthcare in Q4, even through full year sales were down slightly.

LONDON- JUNE, 2018: The GlaxoSmithKline headquarters building in Brentford, west London. A British global pharmaceuticals company.
• Source: Shutterstock

GlaxoSmithKline is now in “full countdown mode” to the demerger of its Consumer Healthcare business, according to CEO Emma Walmsley.

Two months on from GSK’s rejection of a £50bn ($68bn) bid for the business from Unilever – and with other...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

BioGaia Takes Probiotics To Netherlands For First Time

 
• By Tom Gallen

Adopting an online approach, BioGaia is set to enter the Dutch market for probiotic dietary supplements. The firm announced the move as it reported lower sales in Q1.

IQVIA Consumer Health: Digestive Category Driving Global OTC Market Growth

 
• By David Ridley

An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.

Dermapharm Seeks To Put Stop To Spanish Slide

 
• By Tom Gallen

Dermapharm shakes up management of Arkopharma subsidiary in Spain with turnaround plan not showing results.

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 
• By Malcolm Spicer

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

More from Business